Rossella Lauria - Concepedia

Author

Rossella Lauria

Also Known As

F Ferraù, Gelsomina Iovane, Lauria, R., M Tatsuta, R LAURIA, R Lauria, R. LAURIA, R. Lauria, Rossella LAURIA, Rossella Lauria

137

Publications

3.8K

Citations

H-Index

Concepts

All Affiliations

University of Naples Federico II Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"University of Campania "Luigi Vanvitelli"Federico II University Hospital Istituti di Ricovero e Cura a Carattere Scientifico

About

Rossella Lauria is an author at University of Naples Federico II specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	28	1.6K
2	Health Sciences	10	11	275
3	Engineering	1	1	21
4	Anatomy	1	1	10
5	Biostatistics	1	1	21

Rossella Lauria

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. Chiara Carlomagno, Francesco Perrone, Ciro Gallo, Journal of Clinical Oncology	1996	409
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros, The Lancet Oncology Advanced Ovarian CancerMedicineMetronomic TherapyGynecologyWeek Versus	2014	386
The prognostic value of lymphatic and blood vessel invasion in operable breast cancer Rossella Lauria, Chiara Carlomagno, Michelino De Laurentiis, Cancer	1995	181
Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study Sabino De Placido, Giovanni Scambia, Giovanni Di Vagno, Journal of Clinical Oncology	2004	164
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial Sandro Pignata, Domenica Lorusso, Florence Joly, The Lancet Oncology Carboplatin-based DoubletMedicineMetronomic TherapyGynecologyPlatinum-sensitive Ovarian Cancer	2021	144
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome Sabrina Chiara Cecere, Gaia Giannone, Vanda Salutari, Gynecologic Oncology MedicineCancer ManagementGynecologyMaintenance TherapyBrca 1–2	2019	103
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial Sabino De Placido, Ciro Gallo, Michelino De Laurentiis, The Lancet Oncology Endocrine OncologyBreast OncologyMedicinePharmacologyEndocrine-sensitive Breast Cancer	2018	86
P46 15 year update of the naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between c-erb-B2 expression and Tamoxifen efficacy Antonio Bianco, Michelino De Laurentiis, Chiara Carlomagno, European Journal of Cancer Year UpdateBreast OncologyOncologyNaples Gun TrialMedicine	1998	78
Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study Tiziana Pagano, Pasquale De Rosa, Roberta Vallone, Menopause The Journal of The North American Menopause Society	2017	76
Erythrocyte Membrane Phospholipid Composition as a Biomarker of Dietary Fat Barbara J. Fuhrman, Maddalena Barba, Vittorio Krogh, Annals of Nutrition and Metabolism	2005	74

Page 1